Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

David Nichols

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Concepts & Ideas

Structure-Activity Relationship

Chemicals & Drugs

Procedures

Radioligand Assay

Physiology

Competitive Binding

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
40
Mailman, Richard
36
Marona-Lewicka, Danuta
21
Johnson, Michael
20
Watts, Val
12
Kurrasch-Orbaugh, Deborah
11
Lawler, Cindy
9
Lewis, Mechelle
8
Barker, Eric
7
Parrish, Jason
6
Sprague, Jon
6
Nelson, DL
5
Braden, Michael
5
chambers, james
4
White, Kellie
4
Monte, Aaron

Sign-in to see all Coauthors

Publications

TOP 3
Marona-Lewicka Danuta; Chemel Benjamin R; Nichols David E
Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI.
Marona-Lewicka Danuta; Nichols David E
WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D(4) receptor activation.
Przybyla Julie A; Cueva Juan P; Chemel Benjamin R; Hsu K Joseph; Riese David J; McCorvy John D; Chester Julia A; Nichols David E; Watts Val J
Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of David Nichols (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Marona-Lewicka Danuta; Chemel Benjamin R; Nichols David E
Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI.
Psychopharmacology 2009;203(2):265-77.
2009: Marona-Lewicka Danuta; Nichols David E
WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D(4) receptor activation.
Behavioural pharmacology 2009;20(1):114-8.
2009: Przybyla Julie A; Cueva Juan P; Chemel Benjamin R; Hsu K Joseph; Riese David J; McCorvy John D; Chester Julia A; Nichols David E; Watts Val J
Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2009;19(2):138-46.
2008: Torres-Altoro Melissa I; White Kellie J; Rodríguez Gustavo J; Nichols David E; Barker Eric L
Helix XI contributes to the entrance of the serotonin transporter permeation pathway.
Protein science : a publication of the Protein Society 2008;17(10):1761-70.
2008: Nichols David E; Frescas Stewart P; Chemel Benjamin R; Rehder Kenneth S; Zhong Desong; Lewin Anita H
High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.
Bioorganic & medicinal chemistry 2008;16(11):6116-23.
2008: Schultz Danielle M; Prescher Jennifer A; Kidd Stephanie; Marona-Lewicka Danuta; Nichols David E; Monte Aaron
'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines.
Bioorganic & medicinal chemistry 2008;16(11):6242-51.
2008: Walline Crystal C; Nichols David E; Carroll F Ivy; Barker Eric L
Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition.
The Journal of pharmacology and experimental therapeutics 2008;325(3):791-800.
2008: Nichols David E; Nichols Charles D
Serotonin receptors.
Chemical reviews 2008;108(5):1614-41.
2008: Parker Matthew A; Kurrasch Deborah M; Nichols David E
The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands.
Bioorganic & medicinal chemistry 2008;16(8):4661-9.
2007: Braden Michael R; Nichols David E
Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor.
Molecular pharmacology 2007;72(5):1200-9.
2007: Banks Matthew L; Sprague Jon E; Kisor David F; Czoty Paul W; Nichols David E; Nader Michael A
Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(10):1840-5.
2007: Marona-Lewicka Danuta; Nichols David E
Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action.
Pharmacology, biochemistry, and behavior 2007;87(4):453-61.
2007: Mu Qiwen; Johnson Kevin; Morgan Paul S; Grenesko Emily L; Molnar Christine E; Anderson Berry; Nahas Ziad; Kozel F Andrew; Kose Samet; Knable Michael; Fernandes Prabhavathi; Nichols David E; Mailman Richard B; George Mark S
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia.
Schizophrenia research 2007;94(1-3):332-41.
2007: George Mark S; Molnar Christine E; Grenesko Emily L; Anderson Berry; Mu Qiwen; Johnson Kevin; Nahas Ziad; Knable Michael; Fernandes Prabhavathi; Juncos Jorge; Huang Xuemei; Nichols David E; Mailman Richard B
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.
Schizophrenia research 2007;93(1-3):42-50.
2007: Selken Jennifer; Nichols David E
Alpha1-adrenergic receptors mediate the locomotor response to systemic administration of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) in rats.
Pharmacology, biochemistry, and behavior 2007;86(4):622-30.
2007: Gallardo-Godoy Alejandra; Torres-Altoro Melissa I; White Kellie J; Barker Eric L; Nichols David E
1-Methylpyridinium-4-(4-phenylmethanethiosulfonate) iodide, MTS-MPP+, a novel scanning cysteine accessibility method (SCAM) reagent for monoamine transporter studies.
Bioorganic & medicinal chemistry 2007;15(1):305-11.
2007: Urban Jonathan D; Clarke William P; von Zastrow Mark; Nichols David E; Kobilka Brian; Weinstein Harel; Javitch Jonathan A; Roth Bryan L; Christopoulos Arthur; Sexton Patrick M; Miller Keith J; Spedding Michael; Mailman Richard B
Functional selectivity and classical concepts of quantitative pharmacology.
The Journal of pharmacology and experimental therapeutics 2007;320(1):1-13.
2006: Braden Michael R; Parrish Jason C; Naylor John C; Nichols David E
Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists.
Molecular pharmacology 2006;70(6):1956-64.
2006: Cueva Juan Pablo; Giorgioni Gianfabio; Grubbs Russell A; Chemel Benjamin R; Watts Val J; Nichols David E
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
Journal of medicinal chemistry 2006;49(23):6848-57.
2006: Parrish Jason C; Nichols David E
Serotonin 5-HT(2A) receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism.
Journal of neurochemistry 2006;99(4):1164-75.
2006: White Kellie J; Kiser Philip D; Nichols David E; Barker Eric L
Engineered zinc-binding sites confirm proximity and orientation of transmembrane helices I and III in the human serotonin transporter.
Protein science : a publication of the Protein Society 2006;15(10):2411-22.
2006: Chemel Benjamin R; Roth Bryan L; Armbruster Blaine; Watts Val J; Nichols David E
WAY-100635 is a potent dopamine D4 receptor agonist.
Psychopharmacology 2006;188(2):244-51.
2006: McLean Thomas H; Parrish Jason C; Braden Michael R; Marona-Lewicka Danuta; Gallardo-Godoy Alejandra; Nichols David E
1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists.
Journal of medicinal chemistry 2006;49(19):5794-803.
2006: McLean Thomas H; Chambers James J; Parrish Jason C; Braden Michael R; Marona-Lewicka Danuta; Kurrasch-Orbaugh Deborah; Nichols David E
C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.
Journal of medicinal chemistry 2006;49(14):4269-74.
2006: Lewis M M; Huang X; Nichols D E; Mailman R B
D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease.
CNS & neurological disorders drug targets 2006;5(3):345-53.
2005: Parrish Jason C; Braden Michael R; Gundy Emily; Nichols David E
Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists.
Journal of neurochemistry 2005;95(6):1575-84.
2005: Ryman-Rasmussen Jessica P; Nichols David E; Mailman Richard B
Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists.
Molecular pharmacology 2005;68(4):1039-48.
2005: Marona-Lewicka Danuta; Thisted Ronald A; Nichols David E
Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.
Psychopharmacology 2005;180(3):427-35.
2005: Gallardo-Godoy Alejandra; Fierro Angélica; McLean Thomas H; Castillo Mariano; Cassels Bruce K; Reyes-Parada Miguel; Nichols David E
Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling.
Journal of medicinal chemistry 2005;48(7):2407-19.
2005: Sprague Jon E; Nichols David E
Neurotoxicity of MDMA (ecstasy): beyond metabolism.
Trends in pharmacological sciences 2005;26(2):59-60; author reply 60-1.
2004: Hrometz Sandra L; Brown Andrew W; Nichols David E; Sprague Jon E
3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B.
Neuroscience letters 2004;367(1):56-9.
2004: Gay Elaine A; Urban Jonathan D; Nichols David E; Oxford Gerry S; Mailman Richard B
Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states.
Molecular pharmacology 2004;66(1):97-105.
2004: Marona-Lewicka Danuta; Nichols David E
Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats.
Psychopharmacology 2004;172(4):415-21.
2004: Grubbs Russell A; Lewis Mechelle M; Owens-Vance Connie; Gay Elaine A; Jassen Amy K; Mailman Richard B; Nichols David E
8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms.
Bioorganic & medicinal chemistry 2004;12(6):1403-12.
2004: Nichols David E
Hallucinogens.
Pharmacology & therapeutics 2004;101(2):131-81.
2004: Sit Sing-Yuen; Xie Kai; Jacutin-Porte Swanee; Boy Kenneth M; Seanz James; Taber Matthew T; Gulwadi Amit G; Korpinen Carolyn D; Burris Kevin D; Molski Thaddeus F; Ryan Elaine; Xu Cen; Verdoorn Todd; Johnson Graham; Nichols David E; Mailman Richard B
Synthesis and SAR exploration of dinapsoline analogues.
Bioorganic & medicinal chemistry 2004;12(4):715-34.
2004: Roman David L; Saldaña Shannon N; Nichols David E; Carroll F Ivy; Barker Eric L
Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters.
The Journal of pharmacology and experimental therapeutics 2004;308(2):679-87.
2003: Kurrasch-Orbaugh Deborah M; Parrish Jason C; Watts Val J; Nichols David E
A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases.
Journal of neurochemistry 2003;86(4):980-91.
2003: Chambers James J; Parrish Jason C; Jensen Niels H; Kurrasch-Orbaugh Deborah M; Marona-Lewicka Danuta; Nichols David E
Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
Journal of medicinal chemistry 2003;46(16):3526-35.
2003: Rodríguez G J; Roman D L; White K J; Nichols D E; Barker E L
Distinct recognition of substrates by the human and Drosophila serotonin transporters.
The Journal of pharmacology and experimental therapeutics 2003;306(1):338-46.
2003: Qandil Amjad M; Lewis Mechelle M; Jassen Amy; Leonard Sarah K; Mailman Richard B; Nichols David E
Synthesis and pharmacological evaluation of substituted naphth[1,2,3-de]isoquinolines (dinapsoline analogues) as D1 and D2 dopamine receptor ligands.
Bioorganic & medicinal chemistry 2003;11(7):1451-64.
2003: Kurrasch-Orbaugh Deborah M; Watts Val J; Barker Eric L; Nichols David E
Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves.
The Journal of pharmacology and experimental therapeutics 2003;304(1):229-37.
2002: Marona-Lewicka Danuta; Kurrasch-Orbaugh Deborah M; Selken Jennifer R; Cumbay Medhane G; Lisnicchia Joshua G; Nichols David E
Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats.
Psychopharmacology 2002;164(1):93-107.
2002: Whiteside Michael S; Kurrasch-Orbaugh Deborah; Marona-Lewicka Danuta; Nichols David E; Monte Aaron
Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes.
Bioorganic & medicinal chemistry 2002;10(10):3301-6.
2002: Nichols David E; Frescas Stewart; Marona-Lewicka Danuta; Kurrasch-Orbaugh Deborah M
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
Journal of medicinal chemistry 2002;45(19):4344-9.
2002: Chambers James J; Kurrasch-Orbaugh Deborah M; Nichols David E
Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT(2A/2C) receptor affinity.
Bioorganic & medicinal chemistry letters 2002;12(15):1997-9.
2002: Chambers James J; Nichols David E
A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor.
Journal of computer-aided molecular design 2002;16(7):511-20.
2002: Falk Erin M; Cook Valerie J; Nichols David E; Sprague Jon E
An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA.
Pharmacology, biochemistry, and behavior 2002;72(3):617-22.
2002: Kilts Jason D; Connery Hilary S; Arrington Elaine G; Lewis Mechelle M; Lawler Cindy P; Oxford Gerry S; O'Malley Karen L; Todd Richard D; Blake Bonita L; Nichols David E; Mailman Richard B
Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs.
The Journal of pharmacology and experimental therapeutics 2002;301(3):1179-89.
2002: Mottola David M; Kilts Jason D; Lewis Mechelle M; Connery Hilary S; Walker Q David; Jones Sara R; Booth Raymond G; Hyslop Deborah K; Piercey Monford; Wightman R Mark; Lawler Cindy P; Nichols David E; Mailman Richard B
Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase.
The Journal of pharmacology and experimental therapeutics 2002;301(3):1166-78.
2002: Sprague Jon E; Leifheit Michael; Selken Jennifer; Milks Michael M; Kinder David H; Nichols David E
In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol.
Synapse (New York, N.Y.) 2002;43(2):118-21.
2002: Kanthasamy A; Sprague J E; Shotwell J R; Nichols D E
Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum.
Neuroscience 2002;114(4):917-24.
2001: Mailman R; Huang X; Nichols D E
Parkinson's disease and D1 dopamine receptors.
Current opinion in investigational drugs (London, England : 2000) 2001;2(11):1582-91.
2001: Tian F; Chang C J; Grutzner J B; Nichols D E; McLaughlin J L
Robinlin: a novel bioactive homo-monoterpene from Robinia pseudoacacia L. (Fabaceae).
Bioorganic & medicinal chemistry letters 2001;11(19):2603-6.
2001: Chambers J J; Kurrasch-Orbaugh D M; Parker M A; Nichols D E
Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists.
Journal of medicinal chemistry 2001;44(6):1003-10.
2001: Laban U; Kurrasch-Orbaugh D; Marona-Lewicka D; Nichols D E
A novel fluorinated tryptamine with highly potent serotonin 5-HT1A receptor agonist properties.
Bioorganic & medicinal chemistry letters 2001;11(6):793-5.
2001: Sprague J E; Worst T J; Haynes K; Mosler C R; Nichols D E; Kane M D
The pharmacodynamic characterization of an antisense oligonucleotide against monoamine oxidase-B (MAO-B) in rat brain striatal tissue.
Cellular and molecular neurobiology 2001;21(1):53-64.
2001: Gulwadi A G; Korpinen C D; Mailman R B; Nichols D E; Sit S Y; Taber M T
Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease.
The Journal of pharmacology and experimental therapeutics 2001;296(2):338-44.
2001: Huang X; Lawler C P; Lewis M M; Nichols D E; Mailman R B
D1 dopamine receptors.
International review of neurobiology 2001;48():65-139.
2000: Blair J B; Kurrasch-Orbaugh D; Marona-Lewicka D; Cumbay M G; Watts V J; Barker E L; Nichols D E
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
Journal of medicinal chemistry 2000;43(24):4701-10.
1999: Gerasimov M; Marona-Lewicka D; Kurrasch-Orbaugh D M; Qandil A M; Nichols D E
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
Journal of medicinal chemistry 1999;42(20):4257-63.
1999: Hoffman B; Cho S J; Zheng W; Wyrick S; Nichols D E; Mailman R B; Tropsha A
Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods.
Journal of medicinal chemistry 1999;42(17):3217-26.
1999: Scorza C; Silveira R; Nichols D E; Reyes-Parada M
Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action.
Neuropharmacology 1999;38(7):1055-61.
1999: Blair J B; Marona-Lewicka D; Kanthasamy A; Lucaites V L; Nelson D L; Nichols D E
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
Journal of medicinal chemistry 1999;42(6):1106-11.
1999: Doll M K; Nichols D E; Kilts J D; Prioleau C; Lawler C P; Lewis M M; Mailman R B
Synthesis and dopaminergic properties of benzo-fused analogues of quinpirole and quinelorane.
Journal of medicinal chemistry 1999;42(5):935-40.
1998: Parker M A; Marona-Lewicka D; Lucaites V L; Nelson D L; Nichols D E
A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor.
Journal of medicinal chemistry 1998;41(26):5148-9.
1998: Vangveravong S; Kanthasamy A; Lucaites V L; Nelson D L; Nichols D E
Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives.
Journal of medicinal chemistry 1998;41(25):4995-5001.
1998: Lieberman J A; Mailman R B; Duncan G; Sikich L; Chakos M; Nichols D E; Kraus J E
Serotonergic basis of antipsychotic drug effects in schizophrenia.
Biological psychiatry 1998;44(11):1099-117.
1998: Mailman R B; Nichols D E
Dopamine D1 receptor agonists as antiparkinson drugs.
Trends in pharmacological sciences 1998;19(7):255-6.
1998: Marona-Lewicka D; Nichols D E
Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents.
Psychopharmacology 1998;138(1):67-75.
1998: Lewis M M; Watts V J; Lawler C P; Nichols D E; Mailman R B
Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency.
The Journal of pharmacology and experimental therapeutics 1998;286(1):345-53.
1998: Monte A P; Marona-Lewicka D; Lewis M M; Mailman R B; Wainscott D B; Nelson D L; Nichols D E
Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
Journal of medicinal chemistry 1998;41(12):2134-45.
1998: Sprague J E; Everman S L; Nichols D E
An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine.
Neurotoxicology 1998;19(3):427-41.
1998: Parker M A; Marona-Lewicka D; Kurrasch D; Shulgin A T; Nichols D E
Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA).
Journal of medicinal chemistry 1998;41(6):1001-5.
1998: Cozzi N V; Frescas S; Marona-Lewicka D; Huang X; Nichols D E
Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential.
Pharmacology, biochemistry, and behavior 1998;59(3):709-15.
1997: Marona-Lewicka D; Nichols D E
5-HT2A/2C receptor agonists potentiate the discriminative cue of (+)-amphetamine in the rat.
Neuropharmacology 1997;36(10):1471-5.
1997: Monte A P; Waldman S R; Marona-Lewicka D; Wainscott D B; Nelson D L; Sanders-Bush E; Nichols D E
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
Journal of medicinal chemistry 1997;40(19):2997-3008.
1997: Negash K; Nichols D E; Watts V J; Mailman R B
Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphth[2,1-b]azepines as rigid analogues of beta-phenyldopamine.
Journal of medicinal chemistry 1997;40(14):2140-7.
1997: Smith H P; Nichols D E; Mailman R B; Lawler C P
Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist.
European journal of pharmacology 1997;323(1):27-36.
1996: Sprague J E; Johnson M P; Schmidt C J; Nichols D E
Studies on the mechanism of p-chloroamphetamine neurotoxicity.
Biochemical pharmacology 1996;52(8):1271-7.
1996: Monte A P; Marona-Lewicka D; Parker M A; Wainscott D B; Nelson D L; Nichols D E
Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups.
Journal of medicinal chemistry 1996;39(15):2953-61.
1996: Marona-Lewicka D; Rhee G S; Sprague J E; Nichols D E
Reinforcing effects of certain serotonin-releasing amphetamine derivatives.
Pharmacology, biochemistry, and behavior 1996;53(1):99-105.
1996: Mottola D M; Laiter S; Watts V J; Tropsha A; Wyrick S D; Nichols D E; Mailman R B
Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.
Journal of medicinal chemistry 1996;39(1):285-96.
1996: Ghosh D; Snyder S E; Watts V J; Mailman R B; Nichols D E
9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
Journal of medicinal chemistry 1996;39(2):549-55.
1996: Nichols D E; Monte A; Huang X; Marona-Lewicka D
Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent.
Behavioural brain research 1996;73(1-2):117-9.
1995: Marona-Lewicka D; Rhee G S; Sprague J E; Nichols D E
Psychostimulant-like effects of p-fluoroamphetamine in the rat.
European journal of pharmacology 1995;287(2):105-13.
1995: Watts V J; Lawler C P; Gonzales A J; Zhou Q Y; Civelli O; Nichols D E; Mailman R B
Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists.
Synapse (New York, N.Y.) 1995;21(2):177-87.
1995: Oberlender R; Ramachandran P V; Johnson M P; Huang X; Nichols D E
Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines.
Journal of medicinal chemistry 1995;38(18):3593-601.
1995: Marona-Lewicka D; Nichols D E
Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists.
Psychopharmacology 1995;120(4):384-91.
1995: Knoerzer T A; Watts V J; Nichols D E; Mailman R B
Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors.
Journal of medicinal chemistry 1995;38(16):3062-70.
1995: Snyder S E; Aviles-Garay F A; Chakraborti R; Nichols D E; Watts V J; Mailman R B
Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro-1H- benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine, 6,7-dihydroxy- 1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(aminomethyl)-9,10- dihydro-1,2-dihydroxyanthracene as conformationally restricted analogs of beta-phenyldopamine.
Journal of medicinal chemistry 1995;38(13):2395-409.
1995: Gilmore J H; Watts V J; Lawler C P; Noll E P; Nichols D E; Mailman R B
"Full" dopamine D1 agonists in human caudate: biochemical properties and therapeutic implications.
Neuropharmacology 1995;34(5):481-8.
1995: Sprague J E; Nichols D E
The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits.
The Journal of pharmacology and experimental therapeutics 1995;273(2):667-73.
1995: Watts V J; Lawler C P; Fox D R; Neve K A; Nichols D E; Mailman R B
LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors.
Psychopharmacology 1995;118(4):401-9.
1995: Sprague J E; Nichols D E
Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum.
Psychopharmacology 1995;118(3):357-9.
1995: Monte A P; Marona-Lewicka D; Kanthasamy A; Sanders-Bush E; Nichols D E
Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.
Journal of medicinal chemistry 1995;38(6):958-66.
1995: Brewster W K; Nichols D E; Watts V J; Riggs R M; Mottola D; Mailman R B
Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands.
Journal of medicinal chemistry 1995;38(2):318-27.
1994: Nichols D E; Frescas S; Marona-Lewicka D; Huang X; Roth B L; Gudelsky G A; Nash J F
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
Journal of medicinal chemistry 1994;37(25):4346-51.
1994: Minor D L; Wyrick S D; Charifson P S; Watts V J; Nichols D E; Mailman R B
Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists.
Journal of medicinal chemistry 1994;37(25):4317-28.
1994: Knoerzer T A; Nichols D E; Brewster W K; Watts V J; Mottola D; Mailman R B
Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist.
Journal of medicinal chemistry 1994;37(15):2453-60.
1994: Marona-Lewicka D; Nichols D E
Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan.
European journal of pharmacology 1994;258(1-2):1-13.
1994: Huang X; Marona-Lewicka D; Pfaff R C; Nichols D E
Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives.
Pharmacology, biochemistry, and behavior 1994;47(3):667-73.
1994: Pfaff R C; Huang X; Marona-Lewicka D; Oberlender R; Nichols D E
Lysergamides revisited.
NIDA research monograph 1994;146():52-73.
1994: Sprague J E; Huang X; Kanthasamy A; Nichols D E
Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan.
Life sciences 1994;55(15):1193-8.
1993: Monte A P; Marona-Lewicka D; Cozzi N V; Nichols D E
Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine.
Journal of medicinal chemistry 1993;36(23):3700-6.
1993: Watts V J; Lawler C P; Gilmore J H; Southerland S B; Nichols D E; Mailman R B
Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents.
European journal of pharmacology 1993;242(2):165-72.
1993: Watts V J; Lawler C P; Knoerzer T; Mayleben M A; Neve K A; Nichols D E; Mailman R B
Hexahydrobenzo[a]phenanthridines: novel dopamine D3 receptor ligands.
European journal of pharmacology 1993;239(1-3):271-3.
1993: Huang X; Nichols D E
5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits.
European journal of pharmacology 1993;238(2-3):291-6.
1993: Kohli J D; Horn P T; Glock D; Brewster W K; Nichols D E
Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist.
European journal of pharmacology 1993;235(1):31-5.
1993: Nichols D E; Marona-Lewicka D; Huang X; Johnson M P
Novel serotonergic agents.
Drug design and discovery 1993;9(3-4):299-312.
1992: Huang X; Marona-Lewicka D; Nichols D E
p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent.
European journal of pharmacology 1992;229(1):31-8.
1992: Mottola D M; Brewster W K; Cook L L; Nichols D E; Mailman R B
Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.
The Journal of pharmacology and experimental therapeutics 1992;262(1):383-93.
1992: Tomaszewski Z; Johnson M P; Huang X; Nichols D E
Benzofuran bioisosteres of hallucinogenic tryptamines.
Journal of medicinal chemistry 1992;35(11):2061-4.
1992: Oberlender R; Pfaff R C; Johnson M P; Huang X M; Nichols D E
Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane.
Journal of medicinal chemistry 1992;35(2):203-11.
1991: Johnson M P; Huang X M; Nichols D E
Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue.
Pharmacology, biochemistry, and behavior 1991;40(4):915-22.
1991: Lovenberg T W; Roth R H; Nichols D E; Mailman R B
D1 dopamine receptors of NS20Y neuroblastoma cells are functionally similar to rat striatal D1 receptors.
Journal of neurochemistry 1991;57(5):1563-9.
1991: Darney K J; Lewis M H; Brewster W K; Nichols D E; Mailman R B
Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1991;5(3):187-95.
1991: Lovenberg T W; Nichols D E; Nestler E J; Roth R H; Mailman R B
Guanine nucleotide binding proteins and the regulation of cyclic AMP synthesis in NS20Y neuroblastoma cells: role of D1 dopamine and muscarinic receptors.
Brain research 1991;556(1):101-7.
1991: Huang X M; Johnson M P; Nichols D E
Reduction in brain serotonin markers by alpha-ethyltryptamine (Monase).
European journal of pharmacology 1991;200(1):187-90.
1991: Johnson M P; Nichols D E
Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats.
Neuropharmacology 1991;30(7):819-22.
1991: Johnson M P; Conarty P F; Nichols D E
[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues.
European journal of pharmacology 1991;200(1):9-16.
1991: Johnson M P; Frescas S P; Oberlender R; Nichols D E
Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA).
Journal of medicinal chemistry 1991;34(5):1662-8.
1991: Oberlender R; Nichols D E
Structural variation and (+)-amphetamine-like discriminative stimulus properties.
Pharmacology, biochemistry, and behavior 1991;38(3):581-6.
1991: Steele T D; Brewster W K; Johnson M P; Nichols D E; Yim G K
Assessment of the role of alpha-methylepinine in the neurotoxicity of MDMA.
Pharmacology, biochemistry, and behavior 1991;38(2):345-51.
1991: Nichols D E; Snyder S E; Oberlender R; Johnson M P; Huang X M
2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines.
Journal of medicinal chemistry 1991;34(1):276-81.
1991: Nichols D E; Johnson M P; Oberlender R
5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine.
Pharmacology, biochemistry, and behavior 1991;38(1):135-9.
1990: Oberlender R; Nichols D E
(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity.
The Journal of pharmacology and experimental therapeutics 1990;255(3):1098-106.
1990: Johnson M P; Huang X M; Oberlender R; Nash J F; Nichols D E
Behavioral, biochemical and neurotoxicological actions of the alpha-ethyl homologue of p-chloroamphetamine.
European journal of pharmacology 1990;191(1):1-10.
1990: Brewster W K; Nichols D E; Riggs R M; Mottola D M; Lovenberg T W; Lewis M H; Mailman R B
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
Journal of medicinal chemistry 1990;33(6):1756-64.
1990: Johnson M P; Nichols D E
Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine.
Pharmacology, biochemistry, and behavior 1990;36(1):105-9.
1990: Nichols D E; Brewster W K; Johnson M P; Oberlender R; Riggs R M
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
Journal of medicinal chemistry 1990;33(2):703-10.
1990: Johnson M P; Mathis C A; Shulgin A T; Hoffman A J; Nichols D E
[125I]-2-(2,5-dimethoxy-4-iodophenyl)aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex.
Pharmacology, biochemistry, and behavior 1990;35(1):211-7.
1990: Nichols D E; Oberlender R
Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs?
Annals of the New York Academy of Sciences 1990;600():613-23; discussion 623-5.
1989: Nichols D E; Oberlender R; Burris K; Hoffman A J; Johnson M P
Studies of dioxole ring substituted 3,4-methylenedioxyamphetamine (MDA) analogues.
Pharmacology, biochemistry, and behavior 1989;34(3):571-6.
1989: Steele T D; Nichols D E; Yim G K
MDMA transiently alters biogenic amines and metabolites in mouse brain and heart.
Pharmacology, biochemistry, and behavior 1989;34(2):223-7.
1989: Nichols D E; Cassady J M; Persons P E; Yeung M C; Clemens J A; Smalstig E B
Synthesis and evaluation of N,N-di-n-propyltetrahydrobenz[f]indol-7-amine and related congeners as dopaminergic agonists.
Journal of medicinal chemistry 1989;32(9):2128-34.
1989: Lovenberg T W; Brewster W K; Mottola D M; Lee R C; Riggs R M; Nichols D E; Lewis M H; Mailman R B
Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist.
European journal of pharmacology 1989;166(1):111-3.
1989: Johnson M P; Nichols D E
Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration.
Pharmacology, biochemistry, and behavior 1989;33(1):105-8.
1989: McKenna D J; Nazarali A J; Hoffman A J; Nichols D E; Mathis C A; Saavedra J M
Common receptors for hallucinogens in rat brain: a comparative autoradiographic study using [125I]LSD and [125I]DOI, a new psychotomimetic radioligand.
Brain research 1989;476(1):45-56.
1989: Nichols D E; Oberlender R
Structure-activity relationships of MDMA-like substances.
NIDA research monograph 1989;94():1-29.
1988: Nichols D E; Lloyd D H; Johnson M P; Hoffman A J
Synthesis and serotonin receptor affinities of a series of enantiomers of alpha-methyltryptamines: evidence for the binding conformation of tryptamines at serotonin 5-HT1B receptors.
Journal of medicinal chemistry 1988;31(7):1406-12.
1988: Oberlender R; Nichols D E
Drug discrimination studies with MDMA and amphetamine.
Psychopharmacology 1988;95(1):71-6.
1987: Johnson M P; Hoffman A J; Nichols D E; Mathis C A
Binding to the serotonin 5-HT2 receptor by the enantiomers of 125I-DOI.
Neuropharmacology 1987;26(12):1803-6.
1987: Oberlender R; Nichols D E; Ramachandran P V; Srebnik M
Tomoxetine and the stereoselectivity of drug action.
The Journal of pharmacy and pharmacology 1987;39(12):1055-6.
1987: Riggs R M; Nichols D E; Foreman M M; Truex L L
Evaluation of isomeric 4-(chlorohydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines as dopamine D-1 antagonists.
Journal of medicinal chemistry 1987;30(10):1887-91.
1987: Riggs R M; McKenzie A T; Byrn S R; Nichols D E; Foreman M M; Truex L L
Effect of beta-alkyl substitution on D-1 dopamine agonist activity: absolute configuration of beta-methyldopamine.
Journal of medicinal chemistry 1987;30(10):1914-8.
1987: Riggs R M; Nichols D E; Foreman M M; Truex L L; Glock D; Kohli J D
Specific dopamine D-1 and DA1 properties of 4-(mono- and -dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno[2,3-c]pyridine analogue.
Journal of medicinal chemistry 1987;30(8):1454-8.
1986: Nichols D E; Hoffman A J; Oberlender R A; Jacob P; Shulgin A T
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
Journal of medicinal chemistry 1986;29(10):2009-15.
1986: Nichols D E; Hoffman A J; Oberlender R A; Riggs R M
Synthesis and evaluation of 2,3-dihydrobenzofuran analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane: drug discrimination studies in rats.
Journal of medicinal chemistry 1986;29(2):302-4.
1984: Nichols D E; Jacob J N; Hoffman A J; Kohli J D; Glock D
C(2)-Methylation abolishes DA1 dopamine agonist activity of 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (6,7-ADTN): steric intolerance by the receptor.
Journal of medicinal chemistry 1984;27(12):1701-5.
1982: Grosso J A; Nichols D E; Kohli J D; Glock D
Synthesis of 2-(alkylamino)-5,6- and -6,7-dihydroxy-3,4-dihydroquinazolines and evaluation as potential dopamine agonists.
Journal of medicinal chemistry 1982;25(6):703-8.
1982: Nichols D E; Lloyd D H; Hoffman A J; Nichols M B; Yim G K
Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes.
Journal of medicinal chemistry 1982;25(5):530-5.
1982: Hathaway B A; Nichols D E; Nichols M B; Yim G K
A new, potent, conformationally restricted analogue of amphetamine: 2-amino-1,2-dihydronaphthalene.
Journal of medicinal chemistry 1982;25(5):535-8.
1981: Jacob J N; Nichols D E; Kohli J D; Glock D
Dopamine agonist properties of N-alkyl-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines.
Journal of medicinal chemistry 1981;24(8):1013-5.
1981: Kothari P J; Hathaway B A; Nichols D E; Yim G K
Synthesis and serotonin-like activity of 2-amino-5,8-dimethoxy-6-methyl-1,2-dihydronaphthalene.
Journal of medicinal chemistry 1981;24(7):882-4.
1981: Migliaccio G P; Shieh T L; Byrn S R; Hathaway B A; Nichols D E
Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy.
Journal of medicinal chemistry 1981;24(2):206-9.
1980: Grosso J A; Nichols D E; Nichols M B; Yim G K
Synthesis and adrenergic blocking effects of 2-(alkylamino)-3,4-dihydroquinazolines.
Journal of medicinal chemistry 1980;23(11):1261-4.

Sign-in to see more